Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Rating of “Buy” from Analysts

Shares of Aura Biosciences, Inc. (NASDAQ:AURA) have received an average recommendation of “Buy” from the seven research firms that are presently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $23.00.

Separately, Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a research report on Friday, January 31st.

Aura Biosciences Price Performance

NASDAQ AURA opened at $7.50 on Monday. The firm has a market capitalization of $374.63 million, a PE ratio of -4.34 and a beta of 0.30. Aura Biosciences has a 12 month low of $6.63 and a 12 month high of $12.38. The company’s 50 day simple moving average is $7.66 and its 200 day simple moving average is $8.67.

Insider Buying and Selling

In other news, insider Los Pinos Elisabet De sold 15,955 shares of the business’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total transaction of $122,374.85. Following the sale, the insider now directly owns 304,692 shares of the company’s stock, valued at $2,336,987.64. The trade was a 4.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders sold 23,045 shares of company stock worth $177,242. Corporate insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Aura Biosciences

A number of institutional investors have recently bought and sold shares of AURA. Charles Schwab Investment Management Inc. boosted its holdings in shares of Aura Biosciences by 2.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company’s stock worth $1,233,000 after buying an additional 3,612 shares during the period. Geode Capital Management LLC lifted its position in shares of Aura Biosciences by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 1,012,799 shares of the company’s stock valued at $8,327,000 after acquiring an additional 3,972 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Aura Biosciences by 27.3% in the 4th quarter. Wells Fargo & Company MN now owns 27,623 shares of the company’s stock worth $227,000 after purchasing an additional 5,930 shares during the period. BNP Paribas Financial Markets purchased a new position in Aura Biosciences during the 4th quarter worth approximately $50,000. Finally, Bank of America Corp DE raised its stake in Aura Biosciences by 20.5% during the 4th quarter. Bank of America Corp DE now owns 51,286 shares of the company’s stock valued at $422,000 after purchasing an additional 8,709 shares during the period. Hedge funds and other institutional investors own 96.75% of the company’s stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.